Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients With Advanced Breast Cancer.

Trial Profile

Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients With Advanced Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2016

At a glance

  • Drugs Azacitidine (Primary) ; Entinostat (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Jun 2014 Status changed from active, no longer recruiting to completed, as per results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Jun 2014 Partial results (in hormone resistant patient cohort) presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top